Pfizer restarts trial recruitment, speeds up antiviral work against COVID-19

In its first-quarter results posted today, Big Pharma Pfizer said it is beginning to reopen some stalled trials and is now months ahead of schedule to develop a potential new med against COVID-19.

A month ago, just as the pandemic was picking up pace in the U.S. and Europe and lockdowns began, Pfizer said it was hitting pause on enrollment in many new and ongoing clinical trials in response to COVID-19.